Xinlitai: SAL0150 has obtained the approval notification for clinical trials.

Sinovac Biotech announced that the company has recently received the approval notice for clinical trial from the National Medical Products Administration, allowing the company to conduct clinical trials of the innovative drug SAL0150 tablets developed independently by the company for blood sugar control in type 2 diabetes patients, obesity or overweight, and type 2 diabetes combined with peripheral artery disease with intermittent claudication.